On 25 March, Ergomed announced their Audited Full Year Results for 2019 showing that the year had been transformational for the company, with revenue of £68.3m (up 26.1%), adjusted EBITDA of £12.5m (up from £2.3m in 2018), an order book of future contracted revenue of £124.1m (up 13.6%) and a new £30m credit facility. Additonally, […]
On 25 March, Ergomed announced their Audited Full Year Results for 2019 showing that the year had been transformational for the company, with revenue of £68.3m (up 26.1%), adjusted EBITDA of £12.5m (up from £2.3m in 2018), an order book of future contracted revenue of £124.1m (up 13.6%) and a new £30m credit facility.
Additonally, Ergomed has their announced involvement in a study at the Papa Giovanni XXIII Hospital in Bergamo, Italy where the siltuximab antibody is being trialed in the treatment of patients with serious respiratory complications caused by COVID-19.
The strong financial results, in addition to the news of Ergomed’s provision of clinical research services for the COVID-19 study, were discussed when Proactive Investors’ Andrew Scott spoke with Ergomed’s Chief Financial Officer, Richard Barfield and Head of Clinical Development, Dr Gordana Tonkovic.
